Back to Awarded Treatment Trials


Awarded Trial: 00-029

Grant ID

00-029

Illness

Schizophrenia

Primary Drug/Intervention

D-serine

Primary Dosage

30 mg/kg/day

Secondary Drug Intervention

N/A

Secondary Dosage

N/A

Other Drug/Intervention

N/A

Other Dosage

N/A

Status

Completed

Investigator

Heresco-Levy

Sample Size

39

Duration of Study Period for Each Subject

6 weeks

Outcome Measurements

PANSS, BPRS

Results

D-serine treatment was associated with significant improvements in negative, positive and depressive symptoms.

Publication

Heresco-Levy U, Javitt DC, Ebstein R, Vass A, Lichtenberg P, Bar G, Catinari S, Ermilov M. D-serine efficacy as add-on pharmacotherapy to risperidone and olazapine for treatment-refractory schizophrenia. Biol Psychiatry. 2005;57:577-585.

Link

http://www.ncbi.nlm.nih.gov/pubmed/15780844

PI Name

Uriel Heresco-Levy

Degree

MD

Center

N/A

Institution

Ezrath Nashim - Herzog Memorial Hospital

Address

P.O. Box 35300

City or Town

Jerusalem

State or Province

N/A

Zip or Postal Code

91351

Country

Israel

Email Address

heresco@md2.huji.ac.il